Empirical Treatment With Carbapenem vs Third-generation Cephalosporin for Treatment of Spontaneous Bacterial Peritonitis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, S.W. | - |
dc.contributor.author | Yoon, J.S. | - |
dc.contributor.author | Park, J. | - |
dc.contributor.author | Jung, Y.J. | - |
dc.contributor.author | Lee, J.S. | - |
dc.contributor.author | Song, J. | - |
dc.contributor.author | Lee, H.A. | - |
dc.contributor.author | Seo, Y.S. | - |
dc.contributor.author | Lee, M. | - |
dc.contributor.author | Park, J.M. | - |
dc.contributor.author | Choi, D.H. | - |
dc.contributor.author | Kim, M.Y. | - |
dc.contributor.author | Kang, S.H. | - |
dc.contributor.author | Yang, J.M. | - |
dc.contributor.author | Song, D.S. | - |
dc.contributor.author | Chung, S.W. | - |
dc.contributor.author | Kim, M.A. | - |
dc.contributor.author | Jang, H.J. | - |
dc.contributor.author | Oh, H. | - |
dc.contributor.author | Lee, C.-H. | - |
dc.contributor.author | Lee, Y.B. | - |
dc.contributor.author | Cho, E.J. | - |
dc.contributor.author | Yu, S.J. | - |
dc.contributor.author | Kim, Y.J. | - |
dc.contributor.author | Yoon, J.-H. | - |
dc.contributor.author | Lee, J.-H. | - |
dc.date.accessioned | 2021-12-03T14:41:47Z | - |
dc.date.available | 2021-12-03T14:41:47Z | - |
dc.date.created | 2021-08-31 | - |
dc.date.issued | 2021-03 | - |
dc.identifier.issn | 1542-3565 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/129141 | - |
dc.description.abstract | Background & Aims: Third-generation cephalosporins (TGCs) are recommended as first-line antibiotics for treatment of spontaneous bacterial peritonitis (SBP). However, antibiotics against multidrug-resistant organisms (such as carbapenems) might be necessary. We aimed to evaluate whether carbapenems are superior to TGC for treatment of SBP. Methods: We performed a retrospective study of 865 consecutive patients with a first presentation of SBP (275 culture positive; 103 with TGC-resistant bacterial infections) treated at 7 referral centers in Korea, from September 2013 through January 2018. The primary outcome was in-hospital mortality. We made all comparisons using data from patients whose baseline characteristics were balanced by inverse probability of treatment weighting. Results: Of patients who initially received empirical treatment with antibiotics, 95 (11.0%) received carbapenems and 655 (75.7%) received TGCs. Among the entire study cohort, there was no significant difference in in-hospital mortality between the carbapenem (25.8%) and TGC (25.3%) groups (adjusted odds ratio [aOR], 0.97; 95% CI, 0.85–1.11; P =. 66). In the subgroup of patients with high chronic liver failure-sequential organ failure assessment (CLIF-SOFA) scores (score of 7 or greater, n = 314), carbapenem treatment was associated with lower in-hospital mortality (23.1%) than in the TGC group (38.8%) (aOR, 0.84; 95% CI, 0.75–0.94; P=.002). In contrast, among patients with lower CLIF-SOFA scores (n = 436), in-hospital mortality did not differ significantly between the carbapenem group (24.7%) and the TGC group (16.0%) (aOR, 1.06; 95% CI, 0.85–1.32; P =. 58). Conclusions: For patients with a first presentation of SBP, empirical treatment with carbapenem does not reduce in-hospital mortality compared to treatment with TGCs. However, among critically ill patients (CLIF-SOFA scores ≥7), empirical carbapenem treatment was significantly associated with lower in-hospital mortality than TGCs. © 2021 AGA Institute | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | W.B. Saunders | - |
dc.title | Empirical Treatment With Carbapenem vs Third-generation Cephalosporin for Treatment of Spontaneous Bacterial Peritonitis | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Seo, Y.S. | - |
dc.identifier.doi | 10.1016/j.cgh.2020.06.046 | - |
dc.identifier.scopusid | 2-s2.0-85102417993 | - |
dc.identifier.wosid | 000640244200016 | - |
dc.identifier.bibliographicCitation | Clinical Gastroenterology and Hepatology, v.19, no.5, pp.976 - 9.86E+07 | - |
dc.relation.isPartOf | Clinical Gastroenterology and Hepatology | - |
dc.citation.title | Clinical Gastroenterology and Hepatology | - |
dc.citation.volume | 19 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 976 | - |
dc.citation.endPage | 9.86E+07 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.subject.keywordPlus | IN-HOSPITAL MORTALITY | - |
dc.subject.keywordPlus | ESCHERICHIA-COLI | - |
dc.subject.keywordPlus | INFECTIONS | - |
dc.subject.keywordPlus | CIRRHOSIS | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | ACQUISITION | - |
dc.subject.keywordPlus | CEFOTAXIME | - |
dc.subject.keywordPlus | EXPOSURE | - |
dc.subject.keywordPlus | FAILURE | - |
dc.subject.keywordPlus | MODEL | - |
dc.subject.keywordAuthor | Ascites | - |
dc.subject.keywordAuthor | Cirrhosis | - |
dc.subject.keywordAuthor | Risk of Death | - |
dc.subject.keywordAuthor | Therapy | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.